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Abstract
Background: Brittle cornea syndrome (BCS) is a rare, generalized connective tissue disorder associated with extreme
corneal thinning and a high risk of corneal rupture. Recessive mutations in transcription factors ZNF469 and PRDM5
cause BCS. Both transcription factors are suggested to act on a common pathway regulating extracellular matrix genes,
particularly fibrillar collagens. We identified bilateral myopic choroidal neovascularization as the presenting feature of
BCS in a 26-year-old-woman carrying a novel PRDM5 mutation (p.Glu134*). We performed immunohistochemistry of
anterior and posterior segment ocular tissues, as expression of PRDM5 in the eye has not been described, or the effects
of PRDM5-associated disease on the retina, particularly the extracellular matrix composition of Bruch’s membrane.
Methods: Immunohistochemistry using antibodies against PRDM5, collagens type I, III, and IV was performed on the
eyes of two unaffected controls and two patients (both with Δ9-14 PRDM5). Expression of collagens, integrins, tenascin
and fibronectin in skin fibroblasts of a BCS patient with a novel p.Glu134* PRDM5 mutation was assessed using
immunofluorescence.
Results: PRDM5 is expressed in the corneal epithelium and retina. We observe reduced expression of major
components of Bruch’s membrane in the eyes of two BCS patients with a PRDM5 Δ9-14 mutation.
Immunofluorescence performed on skin fibroblasts from a patient with p.Glu134* confirms the generalized nature of
extracellular matrix abnormalities in BCS.
Conclusions: PDRM5-related disease is known to affect the cornea, skin and joints. Here we demonstrate, to the best
of our knowledge for the first time, that PRDM5 localizes not only in the human cornea, but is also widely expressed in
the retina. Our findings suggest that ECM abnormalities in PRDM5-associated disease are more widespread than
previously reported.
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Background
Brittle cornea syndrome (BCS) is an autosomal recessive
connective tissue disorder predominantly affecting the cor-
nea, skin and joints [1–4]. Extreme corneal thinning (220–
450 μm) (normal range 520–560 μm) is the hallmark of the
condition and affected individuals are at high risk of corneal
rupture, leading to irreversible blindness [1, 2]. Other ocu-
lar features include blue sclerae, keratoconus, keratoglobus
and high myopia. Extra-ocular manifestations include deaf-
ness, joint hypermobility, skin hyperelasticity, arachnodac-
tyly, and developmental dysplasia of the hip [2]. BCS has
been described in patients in the absence of extra-ocular
features [2] and diagnosis prior to ocular rupture is possible
in the presence of a high index of clinical suspicion.
BCS results from mutations in one of two genes;
ZNF469, encoding zinc finger protein 469 (BCS type 1
[MIM 229200]) [3] and PRDM5, encoding PR domain-
containing protein 5 (BCS type 2 [MIM 614161]) [4].
Both ZNF469 and PRDM5 proteins are suggested to act
on a common pathway regulating extracellular matrix
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(ECM) gene expression [2–5]. A previous study using
chromatin immunoprecipitation (ChIP) - sequencing has
shown a direct role for PRDM5 in the regulation of col-
lagen genes [6].
A role for PRDM5 in bone development [6] and cor-
neal development and maintenance [4] has been sug-
gested. However, the exact localization of the protein in
the human eye has not been described. We performed
immunohistochemistry (IHC) in human eyes and found
that PRDM5 localizes both to the corneal epithelium
and the retina. Aiming to gain insights into a role for
this protein in the retina, we examined the deposition of
ECM proteins in the retinas of BCS patients with a
PRDM5 Δ9–14 mutation using IHC, and found ECM
abnormalities within Bruch’s membrane. We also report
abnormal expression of ECM components in fibroblasts
from a BCS patient with high axial myopia and choroidal
neovascularization carrying a novel p.Glu134* mutation
in PRDM5, a patient who had not sustained a corneal
rupture. These data suggest that ECM abnormalities in
PRDM5-related disease are more widespread than previ-
ously reported, and suggest a role for PRDM5 in the
retina.
Methods
Participants and clinical evaluation
Informed written consent was obtained and investiga-
tions conducted in accordance with the principles of the
Declaration of Helsinki, with Local Ethics Committee
approval (NHS Research Ethics Committee reference
06/Q1406/52). Patients with BCS P1 and P2, with
PRDM5 Δ9–14; and P3, with PRDM5 p.Arg590* have
been previously described [4]. Diagnosis of BCS in P4,
with PRDM5 p.Glu134*, was based on clinical examin-
ation and confirmed by mutation analysis of ZNF469
and PRDM5. Detailed ophthalmic examinations included
anterior segment examination by slit lamp biomicroscopy,
measurement of corneal thickness using pachymetry, reti-
noscopy, color photography, fluorescein angiography, and
optical coherence tomography (OCT). A systemic workup
including full blood count, coagulation screen and renal
function analyses was performed.
Clinical samples
BCS-affected ocular tissue was obtained from the Depart-
ment of Histopathology, Manchester Royal Infirmary. Hu-
man ocular tissue samples from control individuals were
obtained from the Manchester Eye Bank (Table 1). In-
formed written consent and ethics committee approval
was granted (14/NW/1495).
Genetic analysis
The open reading frames of ZNF469 and PRDM5 were se-
quenced as described [3, 4]. Variants identified in PRDM5
were checked against control data sets including dbSNP
(Build 137) (http://www.ncbi.nlm.nih.gov/SNP), the 1000
Genomes Project (May 2012 release) (http://browser.
1000genomes.org/index.html), and the NHLBI Exome Se-
quencing Project (http://evs.gs.washington.edu/EVS).
Immunoblotting
Fibroblast cell lysis and preparation of nuclear extracts
was performed according to Schnitzler GR [7]. Total
protein content was quantified using a BioRad protein
quantification BCA assay (BioRad Laboratories). Skin fi-
broblasts nuclear extracts were subjected to standard
SDS-PAGE using a custom-made antibody PRDM5 Ab2
[6, 8] at a concentration of 1 μg/ml, and GAPDH at a
concentration of 2 μg/ml (Santa Cruz sc-47724) on
equal amounts of nuclear fraction protein. Membranes
were blocked with TBST (0.1 % Tween 20) containing
5 % non-fat dry milk, and incubated with primary anti-
bodies overnight. Visualization was performed with an
Table 1 Clinical samples used for study
Clinical samples Age Sex Pathology PRDM5
mutation
Functional consequence of mutation Application Reference
IHC – human eye
WB – skin fibroblasts
IF – skin fibroblasts
P1 10 M BCS Δ 9–14 exons Shortened, internally deleted protein product IHC/WB [4]
P2 21 F BCS Δ 9–14 exons Shortened, internally deleted protein product IHC/Q-PCR/WB [4]
P3 8 M BCS Arg590* Truncated protein product Q-PCR/WB [4]
P4 26 F BCS p.Glu134* Presumed null Case report/IF
Control post-mortem eye #1 70 F None Wild-type IHC
Control post-mortem eye #2 58 M None Wild-type IHC
Control skin fibroblasts #1 12 M None Wild-type IF/WB [4]
Control skin fibroblasts #2 19 F None Wild-type IF [4]
IHC Immunohistochemistry, WB Western blotting, IF Immunofluorescence
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enhanced chemiluminescence western blotting kit (Cell
Signalling Technologies #7003).
Histology and immunohistochemistry
Histological analysis was carried out in accordance with
standard diagnostic protocols. 4 μm paraffin-embedded
slides were stained with hematoxylin and eosin and elas-
tin with van Gieson. Immunohistochemistry was per-
formed using PRDM5 Ab2 [6, 8] and mouse monoclonal
antibodies against collagen I (ab90395, Abcam); collagen
III (ab6310, Abcam) and collagen IV (ab6311, Abcam).
PRDM5 AB2 epitope is situated within the region corre-
sponding to N- terminal amino acids 60–142. Staining
was performed on a Ventana Benchmark XT Automated
Immunostaining Module (Ventana Medical Systems) to-
gether with the XT ultraView Universal Red Alkaline
Phosphatase detection system for all antibodies except
PRDM5, where DAB was used as the chromogen. Antigen
retrieval was performed separately using heat-induced
antigen retrieval for PRDM5, and no pre-treatment for
collagens I, III and IV. Primary antibodies were diluted in
Dako REAL™ Antibody Diluent (Dako, Agilent Technolo-
gies, UK) to the indicated optimal dilutions of 3.5 μg/ml
for PRDM5; 3 μg/ml for collagen I; 10 μg/ml for collagen
III; 2.5 μg/ml for collagen IV. Sections of patient eye tissue
were processed in parallel with the control tissue and were
collected, sorted and fixed in an identical manner. Tissue
section slides were masked for origin and scored for de-
tection of cells showing nuclear PRDM5 staining subject-
ively by an independent human observer using a binary
scale (positive or negative). Tissues were considered posi-
tive when >20 % of the cells displayed nuclear PRDM5
staining [8].
Cell culture and immunofluorescence (IF)
Polyclonal rabbit anti-fibronectin (FN) antibody, mouse
anti-tenascin monoclonal antibody (clone BC-24), recog-
nizing all the tenascins (TNs), and TRITC- conjugated
rabbit anti-goat antibody were from Sigma Aldrich;
mouse anti-α5β1 (clone JBS5) and anti-α2β1 (clone
BHA.2) integrin monoclonal antibodies; and goat anti-
type I collagen, anti-type III collagen and anti-type V
collagen antibodies were from Millipore Chemicon Int.
Inc. (Billerica, MA). FITC- and TRITC-conjugated goat
anti-rabbit and anti-mouse secondary antibodies were
from Calbiochem-Novabiochem Int. (San Diego, CA,
USA). Antibody dilutions were: anti-tenascin and anti-
α5β1: 2 μg/ml; anti-α2β1: 4 μg/ml; anti-FN and anti-type I
collagen, 10 μg/ml; anti-type III and type V collagen:
20 μg/ml. Primary dermal fibroblast cultures were estab-
lished from skin biopsies by routine procedures, main-
tained and harvested as described [9, 10]. 1.0 × 105 cells
were grown for 48 h on glass coverslips, fixed in methanol
and incubated with the specified antibodies as reported
[9, 10]. For analysis of integrins, cells were fixed in 3 %
paraformaldehyde and 60 mM sucrose, and perme-
abilized in 0.5 % Triton X-100. Cells were reacted for
1 h at room temperature with 1 μg/ml anti-α5β1 and
anti-α2β1 integrin monoclonal antibodies. Cells were
subsequently incubated with 10 μg/ml FITC- or TRITC-
conjugated secondary antibodies. IF signals were acquired
by a CCD black/white TV camera (SensiCam-PCO Com-
puter Optics GmbH, Germany) mounted on a Zeiss
fluorescence-Axiovert microscope, and digitalized by Image
Pro Plus program (Media Cybernetics, Silver Spring, MD).
Quantitative PCR
Extracted total RNA was reverse-transcribed into single-
stranded cDNA using a High Capacity RNA-to-cDNA
Kit (Life Technologies, Paisley, UK), according to the
manufacturer’s instructions. RT-PCR and data analysis
was performed as previously described [4]. The assay
numbers for the mRNA endogenous control (GAPDH)
and target gene were: GAPDH (Hs02758991_g1*) and
ITA8 (Hs00233321_m1*) (Life Technologies). Cycles to
threshold (CT) values were determined for each sample
and its matched control and relative mRNA expression
levels determined by the 2−ΔΔCt method, providing the
fold change value [11]. Error bars representing 95 %
confidence intervals around the mean are represented
for all experiments. P-values were derived using the 2-
tailed T-test with significance level set at 0.01 to compare
results between mutant and wild-type cells. One-way
ANOVA and Dunnett’s multiple comparison posttest
using mean values and standard error were also per-
formed on fold change means in all groups assessed.
Results
PRDM5 mutations, functional consequences, and
associated phenotypes
A summary of clinical samples used in this study is
shown in Table 1. The mutation PRDM5 Δ9–14, carried
by P1 and P2 (whose clinical details are described in
Burkitt-Wright et al. [4]), is an in-frame deletion muta-
tion that we show here results in the production of a
smaller, internally deleted protein confirmed by western
blot analysis on skin fibroblasts of P1 (Fig. 1). The muta-
tion p.Arg590* (P3) (whose description is also provided
in Burkitt-Wright et al. [4]), also results in a protein
truncation confirmed by western blot analysis on skin fi-
broblasts (Fig. 1). P4 is a 26-year-old woman who pre-
sented with decreased vision in her left eye (LE) in the
context of normal birth, developmental and family his-
tory. Of note she had been seen four years previously in
an identical setting with similar symptoms in her right
eye (RE), resulting in RE permanent visual loss. On
examination best-corrected visual acuity measured 0.16
RE and 0.4 LE (Snellen decimal equivalent). Blue sclera,
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corneal thinning with central corneal thicknesses of
276 μm RE and 281 μm LE (Fig. 2a), and high myopia
were present (spherical equivalent refraction: −12.50 RE
and −13.75 LE). Axial lengths were increased in both
eyes (28 mm) (IOLMaster, Carl Zeiss Meditec Inc, Jena,
Germany). Dilated retinal examination demonstrated a
disciform-like scar in her RE and evidence of active
choroidal neovascularization (CNV) in her LE (Fig. 2b
and c, arrows), leading to retinal exudation (Fig. 2d,*).
Management of CNV consisted of three consecutive
monthly intravitreal injections of the anti-vascular endo-
thelial growth factor (VEGF) agent ranibizumab (Lucentis,
Novartis, Basel, Switzerland), achieving a complete
resolution of the exudation and significant VA im-
provement to 0.70. In a follow-up period of 5 years
there has been no disease recurrence. Systemic exam-
ination showed marfanoid habitus, scoliosis, arachno-
dactyly and hyperextensible joints. Genetic analyses
revealed a novel homozygous nonsense mutation in
PRDM5, c.400G > T p.Glu134*, confirming a diagnosis
of BCS. The mutated nucleotide is in exon 4 (Fig. 2e)
and is predicted to result in nonsense-mediated decay.
This variant was not present in dbSNP132, the Exome
Variant Server, or the 1000 Genomes Project (all
accessed January 5th 2015). Western blot analysis on
skin fibroblasts of P4 did not detect a protein product,
however overlap between the location of the mutation,
and location of the antibody epitope was present.
PRDM5 is expressed in the adult human cornea and
retina
Investigation of PRDM5 expression by immunohisto-
chemistry shows nuclear PRDM5 expression in the cor-
neal epithelium (Fig. 3a) and extensive nuclear and
cytoplasmic PRDM5 expression in the retina (Fig. 3c),
with absent expression in the retinal pigment epithelium
(Fig. 3e, arrow) (control post-mortem eye #2). PRDM5
staining was also not apparent in Bruch’s membrane. Ex-
pression was seen in cells of neuroectodermal origin par-
ticularly the retina, with the exception of nuclei of the
smooth muscle of the ciliary body (mesodermal origin)
and nuclei of the corneal epithelium (surface ectodermal
origin) (Fig. 3 and Additional file 1: Table S1). Immuno-
histochemistry using PRDM5 Ab2 in P1 demonstrates
loss of PRDM5 retinal nuclear and cytoplasmic staining
(Fig. 3e).
Structural abnormalities in Bruch’s membrane in BCS
patients
Two patients, cousins, aged 10 (P1) and 21 (P2) with
PRDM5-associated disease (previously described by
Burkitt-Wright et al. [4]) were studied in order to assess
whether there are any functional consequences to their
retinas. As collagen expression is associated with PRDM5
levels, we studied the expression of PRDM5, collagens I,
III, IV and elastin in Bruch’s membranes of eyes from
these two subjects. Both patients carried a large homozy-
gous deletion (Δ exons 9–14) in PRDM5. The axial
lengths of the two eyes were 20 mm (P1) and 21.8 mm
(P2), determined histologically. We found absent or de-
creased staining in Bruch’s membrane for collagens type I,
III and IV in both BCS samples versus a control sample
(Fig. 4). Van Gieson staining demonstrated normal elastin
staining of Bruch’s membrane in both samples (Additional
file 1: Figure S1). No histological evidence of breaks in
Bruch’s membrane was evident.
Extracellular matrix abnormalities in skin fibroblasts from
BCS patient P4 with the novel PRDM5 mutation p.Glu134*
Indirect immunofluorescence performed on skin fibro-
blasts from patient P4 showed downregulation of struc-
tural collagens I and III, fibronectin, all the tenascins
(detected by a single antibody), and integrin receptors
α2β1 and α5β1. The expression of type V collagen was
disorganized in comparison to the control (Fig. 5).
Discussion
PRDM5-related disease is known to affect the cornea,
skin and joints [1–5]. Here we show that PRDM5 local-
izes not only in the human cornea, but is also widely
expressed in the retina. PRDM5 expression has been re-
ported to be predominantly nuclear, for example in in-
testinal crypts where stem cells reside, with cytoplasmic
Fig. 1 Functional effects of PRDM5 mutations. Western blot using
antibody PRDM5 Ab2 in skin fibroblasts from patients P1 with deletion
of exons 9–14 and P3 with p.Arg590* (described by Burkitt-Wright
et al. [4]), and an unaffected age-matched control (WT). The in-frame
deletion of exons 9–14 (P1) produces a smaller protein of approximately
45 kDa that is consistent with the predicted mass. The p.Arg590*
nonsense mutation is in the last exon of PRDM5 and results in a protein
of approximately 70 kDa, consistent with the predicted mass of the
PRDM5 protein resulting from the truncated transcript. The WT protein
from the unaffected control gives a band of the expected mass
(78 kDa). A non-specific band at 60 kDa is present in all samples. P4
protein from a patient with the presumed null mutation p.Glu134*
does not produce any bands other than the non-specific band
at 60 kDa
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expression in some tissues, including colonic villi [8].
We show both cytoplasmic and nuclear PRDM5 expres-
sion in the retina. We show reduced expression of major
collagenous components of Bruch’s membrane [12]
(Additional file 1: Figure S2) in two patients with a dele-
tion of exons 9–14 of PRDM5 (Fig. 4). An association
between PRDM5 and altered collagen expression has
been shown in previous studies [4–6]. Here we show
that PRDM5 mutations lead to notable differences in the
expression of ECM proteins in Bruch’s membrane that
may impinge on its structural integrity.
We identified myopic choroidal neovascularization
(CNV) [13] in a 26-year old lady with PRDM5-related
BCS, suspected to have the disease due to the presence
of corneal thinning and marfanoid features. High myopia
is a significant risk factor for the development of both
CNV and retinal detachment [13] and has been described
in a number of patients with BCS [2]. Patients with BCS
may therefore benefit from daily monocular monitoring
with an Amsler chart, to detect early metamorphopsia
(visual distortion), with urgent referral to an ophthalmolo-
gist if metamorphopsia develops. CNV has been described
in a number of connective tissue disorders including pseu-
doxanthoma elasticum [14], Beals-Hecht syndrome [15],
Ehlers-Danlos syndrome [16], and osteogenesis imperfecta
[17]. Associations between connective tissue disease and
CNV have however seldom been investigated at the histo-
logical and cellular levels. PRDM5 mutations may further
contribute to weaknesses at the level of Bruch’s membrane
caused by myopia, a hypothesis consistent with our immu-
nohistochemical results, although IHC was only per-
formed on two patients with a PRDM5 Δ9-14, which
results in the production of a truncated protein product.
Retinal basement membrane abnormalities have been also
Fig. 2 A case of PRDM5-associated disease presenting with myopic choroidal neovascularization. a. Corneal topography of right eye (OD) and left
eye (OS) in patient P4 demonstrating marked corneal thinning, with central corneal thickness measuring 276 μm right eye and 281 μm left eye.
b. Retinal photograph of RE (upper left panel) and LE (upper right panel) demonstrating evidence of disciform-like scarring in the macular region of
the RE (arrow), and active choroidal neovascularization in the LE (arrow) leading to retinal exudation. Disc pallor and choroidal thinning are also
present, related to the high refractive error of P4. c. Two fluorescein angiogram images of the LE taken at the time of presentation. Early phase
(left panel) and late phase (right panel). An area of exudation indicative of vascular leakage into the retina is evident, suggestive of predominantly
classic choroidal neovascularization. d. Optical coherence tomography scan of the LE at baseline demonstrating the presence of vascular
exudation into the retina (*). e. Schematic of PRDM5 protein showing the novel mutation p.Glu134*; PRDM5 deletion exons 9–14; and p.Arg590*.
f. Amino acid conservation in 11 species upstream and flanking the mutation p.Glu134*. The alignment was generated using Alamut v2.3
(Interactive Biosoftware, 2013)
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noted upon ultrastructural studies of retinas from patients
with Alport syndrome, caused by mutations in different
transcripts of the collagen IV gene [18].
We looked at expression of fibronectin, integrins and
tenascins in dermal fibroblasts. Fibronectin is present in
Bruch’s membrane (Additional file 1: Figure S2), and
integrins α2β1 and α5β1 are the major integrin receptors
for collagen and fibronectin, respectively. Integrin α8 is
the major tenascin receptor [19] and homozygous muta-
tions in tenascin X cause a subtype of Ehlers-Danlos
syndrome [20, 21]. When present in dermal fibroblasts,
the PRDM5 p.Glu134* mutation results in the absence
of tenascin staining (Fig. 5). These findings are consist-
ent with our previous study examining patient fibro-
blasts from patients with the Δ9–14 and p.Arg590*
PRDM5 mutations [4]. Here we confirm that expression
of integrins α2β1, α5β1 is markedly reduced (Fig. 5). We
also note reduced RNA expression levels of integrin α8
in two patients (Additional file 1: Figure S3). Integrin α8
is the major tenascin receptor [19]. Tenascins are a fam-
ily of four extracellular matrix proteins, tenascin X and
C are major isoforms expressed in ocular tissues [22].
The altered expression of collagen V in fibroblasts lack-
ing PRDM5, together with the absence of tenascins, is
reminiscent of a subtype of autosomal recessive Ehlers-
Danlos syndrome characterized by tenascin X deficiency
[20, 21]. Tenascin X is a large ECM glycoprotein abun-
dantly expressed during development and in adult tissue
strongly associated with ocular basement membranes
(Bowman’s layer and Descemet’s membrane in particu-
lar) [22]. Our data suggests that PRDM5 may play a role
in the regulation of collagen, integrin and tenascin ex-
pression, proteins that participate in ocular basement
membrane development including Bruch’s membrane
Fig. 3 PRDM5 expression in the adult human eye (a–d) (control #2, Table 1). Image objective magnifications (OM) are shown. PRDM5 staining is
brown (obtained using DAB as the chromogen). a. Nuclei of the corneal epithelium are positive for PRDM5 (arrow). The corneal stroma shows
mild cytoplasmic staining, but nuclei are negative (<). b. PRDM5 is not expressed in the corneal endothelium (arrow) (in this image the
endothelium has become detached from the overlying stroma). c. Positive PRDM5 nuclear and cytoplasmic staining in the inner (*) and outer
nuclear layers (**), with cones staining more strongly than rods. Ganglion cell cytoplasm are also positive (arrow). Ocular tissue from patient P1
with deletion exons 9–14 is shown in (e). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; PR, photoreceptors, RPE;
retinal pigment epithelium. d. Retinal pigment epithelium cell nuclei (arrow) appear negative. e. PRDM5 staining in P1 with PRDM5 deletion exons
9–14, demonstrating loss of PRDM5 nuclear and most cytoplasmic staining in the retina associated with loss of antibody epitope
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Fig. 4 Changes in extracellular matrix collagens in Bruch’s membrane in PRDM5-associated disease. Immunohistochemistry performed for collagens I,
III and IV (red stain, obtained using the XT ultraView Universal Red Alkaline Phosphatase detection system) in retinas of a control individual, and BCS
patients P1 and P2 (OM 40×). Absence of staining for collagens I, III and IV in Bruch’s membrane (arrow) is present in sample P1, and absent staining
for collagen I with reduced staining for collagens III and IV in P2. Images were recorded and processed identically to allow direct comparisons to be
made between them
Fig. 5 Expression of ECM components in dermal fibroblasts expressing or lacking PRDM5. Indirect immunofluorescence microscopy performed on
dermal fibroblasts from a control (#2) and BCS patient P4 carrying the PRDM5 p.Glu134* mutation for collagens I, III and V, fibronectin, tenascins and
integrin receptors α2β1 and α5β1. In control cells, collagen I is primarily expressed in the cytoplasm, with only limited expression extracellularly.
Collagen I labelling is substantially reduced in PRDM5 mutant cells. Collagen III appears well organized in the ECM of control cells but was absent in
the mutant fibroblasts where only diffuse cytoplasmic staining was visible. Furthermore, disarray of collagen V was evident with cytoplasmic
accumulation and reduced extracellular matrix in the PRDM5 mutant cells. Expression of the collagen integrin receptor α2β1 was essentially abolished,
with marked reduction in the fibronectin integrin receptor α5β1 and disorganization of fibronectin matrix, in PRDM5 mutant cells compared to control
cells. Tenascins were organized in an abundant extracellular matrix in control cells whereas they were not detectable in the PRDM5 mutant cells. 1 cm
on the image scale corresponds to 16 μm. Images were all recorded under identical parameters to allow for direct comparison
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[12, 22]. A role for PRDM5 as a direct activator of colla-
gen genes has been reported with direct binding of
PRDM5 in conjunction with RNA polymerase II shown
in a ChIP-sequencing experiment performed on murine
MC3T3 cells (6). This role is also supported by the ob-
servation of a significant downregulation of structural
collagens in fibroblasts of patients with BCS2 (4). While
it is also possible that the basement membrane struc-
tural abnormalities observed in Bruch’s membrane also
involve the corneal endothelial and/or epithelial base-
ment membranes, the presence of extreme corneal scar-
ring and ECM changes linked to tissue remodelling
precluded this analysis.
Conclusions
PDRM5-related disease is known to affect the cornea, skin
and joints. Our study shows expression of PRDM5 in the
human cornea and retina, and demonstrates downregula-
tion of major structural components of Bruch’s membrane
in the eyes of two patients with BCS type 2. These findings
suggest that ECM abnormalities in PRDM5-associated
disease are more widespread than previously reported.
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